Month: October 2020
Excerpt from the Article: In a groundbreaking, world-first clinical trial, a team of researchers from Sunnybrook Health Sciences Centre and University Health Network are using focused ultrasound technology to deliver a therapeutic directly to affected brain regions in patients with Parkinson’s disease (PD). Parkinson’s affects more than 6 million people around the world. It is…
Read MoreExcerpt from the Press Release: SAN CARLOS, Calif., Oct. 20, 2020 /PRNewswire/ — IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer’s FDA-approved CCR5 antagonist Maraviroc. The trial “Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2″seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for…
Read MoreExcerpt from the Press Release: BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX:…
Read MoreExcerpt from the Press Release: OAKLAND, Calif.–(BUSINESS WIRE)–Fabric Genomics, a global leader in clinical interpretation of genomic data, announced today the launch of Fabric GEM, a novel algorithm that quickly and efficiently identifies the likely genetic cause of rare diseases from next-generation sequencing data – enabling faster diagnosis and the possibility of faster and more…
Read MoreExcerpt from the Article: When Moderna began research on a vaccine for the virus now known as SARS-CoV-2 in late January, confirmed cases of infection were largely contained within China and the public health catastrophe that’s since unfolded was a threat, not reality. The prospect of designing, testing, and proving a vaccine within a year…
Read MoreCheck out the latest from The Readout Loud podcast: “Whose voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Helen Branswell joins us to…
Read MoreExcerpt from the Press Release: CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) — A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) (collectively the “Investor Group”) together with Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT), a leader in precision genetic medicine for rare…
Read MoreLast week we held our fourth virtual networking meeting in our ongoing series called Ask us Anything In Clinical Research. For our fourth meeting we covered the topic of Contract Research Organizations and Outsourcing. Our guest for this meeting was Peter Heessels, Vice President of Business Development for JSS Research. Thank you to everyone who…
Read MoreExcerpt from the Press Release: SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients. The Brazil study is a Phase 2, Randomized,…
Read MoreExcerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. The collaborative team, led by Dr. Rebecca Powell, Assistant Professor…
Read More